Regulatory Biogen’s salanersen gains FDA breakthrough therapy designation for SMA Pharmaceutical Business ReviewThis advance recognises preliminary data indicating that salanersen may show substantial improvement over existing therapies for SMA.NeuroscienceRead full story pharminent June 5, 2026 (Last updated: June 5, 2026) Pharmaceutical Business Review This advance recognises preliminary data indicating that salanersen may show substantial improvement over existing therapies for SMA. Neuroscience Read full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: Pfizer signs licence agreement with Chai for AI drug discoveryNext: Pharma is betting big on PD-1/VEGF bispecifics. But are companies chasing the wrong target? Related Stories Regulatory Celcuity gets FDA nod for first-in-class breast cancer drug pharminent July 15, 2026 Regulatory FDA clears at-home start dose for Alzheimer’s drug Leqembi pharminent July 14, 2026 Regulatory FDA posts new rejection letters days after confirming pause pharminent July 13, 2026
